Results 151 to 160 of about 21,171,014 (388)

Clinical perspectives of emerging pathogens in bleeding disorders. [PDF]

, 2006
As a result of immunological and nucleic-acid screening of plasma donations for transfusion-transmissible viruses, and the incorporation of viral reduction processes during plasma fractionation, coagulation-factor concentrates (CFC) are now judged safe ...
Bozzette, Samuel, Diamond, Michael, Koerper, Marion A, Kulkarni, Roshni, Ludlam, Christopher A, Powderly, William G, Ritchie, Bruce, Siegel, Jamie, Simmonds, Peter, Stanley, Samuel, Tapper, Michael L, von Depka, Mario   +11 more
core   +1 more source

Paraneoplastic acquired haemophilia A in extensive-stage small cell lung cancer (ES-SCLC) in the era of immunotherapy

, 2021
Mehrnoosh Pauls, Natalia Rydz, Nancy Nixon, Doreen A. Ezeife   +3 more
openalex   +2 more sources

Recombinant B‐domain‐deleted porcine sequence factor VIII (r‐pFVIII) for the treatment of bleeding in patients with congenital haemophilia A and inhibitors

Haemophilia, 2017
Development of inhibitors to human FVIII (hFVIII) significantly complicates the control of bleeding events in patients with haemophilia A.
Johnny Mahlangu, T. Andreeva, D. Macfarlane, Christopher E. Walsh, N. Key   +4 more
semanticscholar   +1 more source

HAEMFIX: Impact of Switching From SHL‐FIX to EHL‐FIX in Patients With Haemophilia B

Haemophilia, EarlyView.
ABSTRACT Introduction Haemophilia B is an X‐linked recessive bleeding disorder caused by coagulation factor IX (FIX) deficiency. Treatment involves intravenous replacement of FIX. Recently, extended half‐life (EHL) FIX products have been introduced alongside standard half‐life (SHL) products to optimize therapy. Aim This study evaluated bleeding rates,
Jasmin Lonardi, Susan Halimeh, Sylvia von Mackensen, Lisa Kleinlein, Juliet Fleischer, Henri Funk, Julia Hölz, Johannes Holzapfel, Sabrina Juranek, Victoria Lieftüchter, Christoph Bidlingmaier, Martin Olivieri   +11 more
wiley   +1 more source

Recent Developments in Immune Tolerance Induction in Haemophilia A [PDF]

, 2007
W. Kreuz, Carmen Escuriola Ettingshausen
openalex   +1 more source

Elucidating the Molecular Basis in a Cohort of Patients With Combined Bleeding Tendencies and Joint Hypermobility Manifestations

Haemophilia, EarlyView.
ABSTRACT Background In patients with unexplained bleeding and normal haemostatic parameters, heritable disorders of connective tissue (HDCT) may be an underlying cause due to vascular fragility, as observed in Ehlers–Danlos syndrome (EDS) or Marfan syndrome (MS). This study aims to investigate the molecular profile of patients with joint hypermobility (
Perla Bandini, Nina Borràs, Carme Altisent, Judith Sánchez‐Raya, Laura Martin‐Fernandez, Iris Garcia‐Martínez, Natàlia Comes, Lorena Ramírez, Marta Martorell, Carlos Hobeich, Francisco Vidal, Irene Corrales   +11 more
wiley   +1 more source

Safety, Efficacy and Treatment Patterns of rIX‐FP in Previously Untreated Paediatric Haemophilia B Patients: A Retrospective Chart Review in Japan

Haemophilia, EarlyView.
Abstract Background Limited real‐world data exist on recombinant fusion protein‐linking coagulation factor IX (FIX) with albumin (rIX‐FP) in paediatric previously untreated patients (PUPs) with haemophilia B, particularly in infants. Aims To evaluate the treatment patterns, safety and efficacy of rIX‐FP in paediatric PUPs in Japan.
Keiji Nogami, Chiai Nagae, Masatoshi Yono, Naoki Terasaka   +3 more
wiley   +1 more source

Recombinant factor VIIa in the management of surgery and acute bleeding episodes in children with haemophilia and high responding inhibitors [PDF]

, 2002
Niamh O’Connell, Corrina Mc Mahon, Jude Smith, Kate Khair, Ian Hann, Ri Liesner, Owen Smith   +6 more
openalex   +1 more source

Post‑Marketing Surveillance of the Safety and Effectiveness of Emicizumab in Japanese Patients With Congenital Haemophilia A With Inhibitors

Haemophilia, EarlyView.
ABSTRACT Introduction The bispecific monoclonal antibody emicizumab was approved for prophylactic treatment of congenital haemophilia A (HA) in Japan in 2018. Aim To monitor long‐term safety and effectiveness of emicizumab, including appropriate concomitant use of bypassing agents (BPAs), in Japanese patients with congenital HA with inhibitors who ...
Midori Shima, Katsuyuki Fukutake, Masanori Matsumoto, Yoshihiko Sugimura, Chiaki Sugita, Lyu Ji, Mika Kawano, Tadashi Matsushita   +7 more
wiley   +1 more source

The unseen risk: A post-traumatic forehead swelling unveiling pseudoaneurysm and haemophilia A

Current Medicine Research and Practice
Superficial temporal artery (STA) pseudoaneurysms are rare in the paediatric population and even more unusual as the initial clinical presentation of incidentally diagnosed haemophilia A.
Alpana Prasad, Kriti Mittal, Shubham Kumar, Manas Kalra   +3 more
doaj   +1 more source